Serum Level of S100B Protein as a Biomarker of Therapeutic Adherence in Parkinson’s Disease Patients
DOI:
https://doi.org/10.31351/vol33iss3pp161-170Keywords:
Parkinson’s disease, neurodegeneration, therapeutic adherence, S100B, MMAS-8Abstract
Pharmacological management of Parkinson’s disease (PD) is complex and may negatively impact patients' adherence to therapy. Several objective and subjective approaches are used to assess therapeutic adherence. Measurement of biological markers, that are well correlated with the effect of the medications, and that are distributed into easily accessible body fluids would be feasible approach for measuring therapeutic adherence for these medications. S100B protein has been proposed to be involved in the pathophysiology of PD. The study aims to measure the serum S100B level in PD patients and to assess its potentials to be used as a biomarker to predict therapeutic adherence in PD patients. Sixty-eight adult outpatients, of both genders, who were already diagnosed with PD, receiving different anti-Parkinson medications, were enrolled in this cross-sectional study. Hoehn and Yahr scale was used to determine the stage of disease; while, therapeutic adherence to treatment was assessed using the Arabic version of Morisky Medication Adherence Scale (MMAS-8). Serum S100B level was measured by enzyme-linked immune sorbent assay. Serum S100B level of participants was 10.55 (13.3) ng/l, and there was no significant difference between medians of S100B protein according to disease stages, P =0.975. Serum S100B level in patients with poor therapeutic adherence [14.2 (13.2) ng/l] was significantly higher than that in patients with good therapeutic adherence [3.14 (3.34)]; P = 0.008. Furthermore, serum S100B level with the MMAS-8; (r= -0.414, P = 0.001). Finally, at a cut-off point 3.57 ng/l and above, serum S100B level was shown to have good potential [area under the curve (AUC)= 0.715], as biomarker of therapeutic adherence with 70.6% sensitivity and 70.6%, specificity; P = 0.008. In conclusion, serum S100B level in PD patients is negatively correlated with therapeutic adherence level and has good potentials as biomarker of therapeutic adherence in PD patients to anti-Parkinson medications.
Received 18/8/2023
Accepted 28/8/2023
Published 15/9/2024
How to Cite
Publication Dates
References
Jankovic J, Tan EK. Parkinson's disease: etiopathogenesis and treatment. Journal of neurology, neurosurgery, and psychiatry. 2020;91(8):795-808.
Simon DK, Tanner CM, Brundin P. Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology. Clinics in geriatric medicine. 2020;36(1):1-12.
Merdaw MA, Kasim AA. Seroprevalence of Toxoplasma Gondii in Parkinson’s Disease Iraqi Patients. Iraqi Journal of Pharmaceutical Sciences. 2021; 30(2):99-105.
Mohamad IH, Rana SA, Saife DA-A. The role of Herpes simplex virus type 1 and 2 in patients with neurodegenerative diseases. Iraqi Journal of Science.2018; 59(4C), 2179–83.
Schrag A, Bohlken J, Dammertz L, Teipel S, Hermann W, Akmatov MK, Bätzing J, Holstiege J. Widening the Spectrum of Risk Factors, Comorbidities, and Prodromal Features of Parkinson Disease. JAMA neurology. 2023;80(2):161-71.
Ou Z, Pan J, Tang S, Duan D, Yu D, Nong H, Wang Z. Global Trends in the Incidence, Prevalence, and Years Lived With Disability of Parkinson's Disease in 204 Countries/Territories From 1990 to 2019. Frontiers in public health. 2021;9:776847.
Safiri S, Noori M, Nejadghaderi SA, Mousavi SE, Sullman MJM, Araj-Khodaei M, Singh K, Kolahi AA, Gharagozli K. The burden of Parkinson's disease in the Middle East and North Africa region, 1990-2019: results from the global burden of disease study 2019. BMC Public Health. 2023;23(1):107.
Straka I, Minár M, Gažová A, Valkovič P, Kyselovič J. Clinical aspects of adherence to pharmacotherapy in Parkinson disease: A PRISMA-compliant systematic review. Medicine. 2018;97(23):e10962.
Sesar A, Arbelo JM, del Val JL. Treatment of Parkinson disease, time and dosage: "does simple dosage facilitate compliance and therapeutic goals?". The neurologist. 2011;17(6 Suppl 1):S43-6.
Bainbridge JL, Ruscin JM. Challenges of treatment adherence in older patients with Parkinson's disease. Drugs & aging. 2009;26(2):145-55.
Grosset KA, Reid JL, Grosset DG. Medicine-taking behavior: implications of suboptimal compliance in Parkinson's disease. Movement disorders: official journal of the Movement Disorder Society. 2005;20(11):1397-404.
Grosset D, Antonini A, Canesi M, Pezzoli G, Lees A, Shaw K, Cubo E, Martinez-Martin P, Rascol O, Negre-Pages L, Senard A, Schwarz J, Strecker K, Reichmann H, Storch A, Löhle M, Stocchi F, Grosset K. Adherence to antiparkinson medication in a multicenter European study. Movement disorders: official journal of the Movement Disorder Society. 2009;24(6):826-32.
Grosset KA, Bone I, Reid JL, Grosset D. Measuring therapy adherence in Parkinson's disease: a comparison of methods. Journal of neurology, neurosurgery, and psychiatry. 2006;77(2):249-51.
Radojević B, Dragašević-Mišković NT, Milovanović A, Svetel M, Petrović I, Pešić M, Tomić A, Stanisavljević D, Savić MM, Kostić VS. Adherence to Medication among Parkinson's Disease Patients Using the Adherence to Refills and Medications Scale. International journal of clinical practice. 2022;2022:6741280.
Hughes CM. Medication non-adherence in the elderly: how big is the problem? Drugs & aging. 2004;21(12):793-811.
Kronish IM, Thorpe CT, Voils CI. Measuring the multiple domains of medication nonadherence: findings from a Delphi survey of adherence experts. Translational behavioral medicine. 2021;11(1):104-13.
Chioncel O, Collins SP, Greene SJ, Ambrosy AP, Vaduganathan M, Macarie C, Butler J, Gheorghiade M. Natriuretic peptide-guided management in heart failure. Journal of Cardiovascular Medicine. 2016;17(8):556-68.
Marenholz I, Heizmann CW, Fritz G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochemical and biophysical research communications. 2004;322(4):1111-22.
Donato R, Sorci G, Bianchi R, Riuzzi F, Tubaro C, Arcuri C, Giambanco I, Donato R. S100B Protein, A Damage-Associated Molecular Pattern Protein in the Brain and Heart, and Beyond. Cardiovasc Psychiatry Neurol. 2010; 2010:656481.
Donato R, Sorci G, Riuzzi F, Arcuri C, Bianchi R, Brozzi F, Tubaro C, Giambanco I. S100B’s double life: intracellular regulator and extracellular signal. Biochim Biophys Acta. 2009;1793(6):1008–22
Liu Y, Buck DC, Neve KA. Novel interaction of the dopamine D2 receptor and the Ca2+ binding protein S100B: role in D2 receptor function. Mol Pharmacol. 2008;74(2):371–8
Cristóvaõ JS, Gomes CM. S100 Proteins in Alzheimer’s Disease. Front Neurosci. 2019; 16;(13):463
Sathe K, Maetzler W, Lang JD, Mounsey RB, Fleckenstein C, Martin HL, Schulte C, Mustafa S, Synofzik M, Vukovic Z, Itohara S, Berg D, Teismann P. S100B is increased in Parkinson's disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathway. Brain : a journal of neurology. 2012;135(Pt 11):3336-47.
Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17(5):427-42.
Ashur ST, Shamsuddin K, Shah SA, Bosseri S, Morisky DE. Reliability and known-group validity of the Arabic version of the 8-item Morisky Medication Adherence Scale among type 2 diabetes mellitus patients. Eastern Mediterranean health journal. 2015;21(10):722-8.
Morisky DE, Ang A, Krousel-Wood M, Ward HJ. Predictive validity of a medication adherence measure in an outpatient setting. Journal of clinical hypertension (Greenwich, Conn). 2008;10(5):348-54.
Safiri S, Noori M, Nejadghaderi SA, Mousavi SE, Sullman MJM, Araj-Khodaei M, Singh K, Kolahi AA, Gharagozli K. The burden of Parkinson’s disease in the Middle East and North Africa region, 1990–2019: results from the global burden of disease study 2019. BMC Public Health. 2023;23(1):107.
Moisan F, Kab S, Mohamed F, Canonico M, Le Guern M, Quintin C, Carcaillon L, Nicolau J, Duport N, Singh-Manoux A, Boussac-Zarebska M, Elbaz A. Parkinson disease male-to-female ratios increase with age: French nationwide study and meta-analysis. Journal of neurology, neurosurgery, and psychiatry. 2016;87(9):952-7.
Chen J, Guan Z, Wang L, Song G, Ma B, Wang Y. Meta-analysis: overweight, obesity, and Parkinson's disease. International journal of endocrinology. 2014;2014:203930.
Kim R, Jun JS. Impact of Overweight and Obesity on Functional and Clinical Outcomes of Early Parkinson's Disease. Journal of the American Medical Directors Association. 2020;21(5):697-700.
Rana AQ, Qureshi AR, Mumtaz A, Abdullah I. Associations of pain and depression with marital status in patients diagnosed with Parkinson's disease. 2016;133(4):276-80.
Valldeoriola F, Coronell C, Pont C, Buongiorno MT, Cámara A, Gaig C, Compta Y. Socio-demographic and clinical factors influencing the adherence to treatment in Parkinson’s disease: the ADHESON study. European Journal of Neurology. 2011;18(7):980-7.
Mohammed O, Al-Hamadani H. Parkinson’s Disease in A Kurdish Population. Iraqi Postgraduate Medical Journal. 2018;17(1):36-44.
Abdullah AF, Niazi AD, Kareem AMA. Prevalence of Parkinson’s disease in Al-Kadhimiya district (Baghdad city): Community- based study. Iraqi Journal of Medical Sciences. 2005;4(2):179-186.
Grosset KA, Bone I, Grosset DG. Suboptimal medication adherence in Parkinson's disease. Movement disorders : official journal of the Movement Disorder Society. 2005;20(11):1502-7.
Abdul-Jabbar MA, Kadhim DJ. Adherence to different treatment modalities among patients on maintenance hemodialysis. Iraqi Journal of Pharmaceutical Sciences. 2022;31(1):95-101.
Alalaqi A, Lawson G, Obaid Y, Tanna S. Adherence to cardiovascular pharmacotherapy by patients in Iraq: A mixed methods assessment using quantitative dried blood spot analysis and the 8-item Morisky Medication Adherence Scale. 2021;16(5):e0251115.
Baiee H, Makai M. Medication adherence in hypertensive diabetic patients. Medical Journal of Babylon. 2022;19(4):569-74.
Allela O, Salih HM, Haji Ahmed I. Adherence to medication and glucose control in diabetic patients in Duhok, Iraq. Pharmacia. 2022;69(3):673-9.
Straka I, Minár M, Škorvánek M, Grofik M, Danterová K, Benetin J, Kurča E, Gažová A, Boleková V, Wyman-Chick KA, Kyselovič J, Valkovič P. Adherence to Pharmacotherapy in Patients With Parkinson's Disease Taking Three and More Daily Doses of Medication. Frontiers in neurology. 2019;10:799.
Aggarwal S, Paul G, Paul BS, Mahendru D, Goyal S. Factors Affecting Adherence to Pharmacotherapy in Parkinson's Disease. Annals of Indian Academy of Neurology. 2021;24(6):879-84.
Schaf DV, Tort AB, Fricke D, Schestatsky P, Portela LV, Souza DO, Rieder CR. S100B and NSE serum levels in patients with Parkinson's disease. Parkinsonism & related disorders. 2005;11(1):39-43.
Carvalho DZ, Schönwald SV, Schumacher-Schuh AF, Braga CW, Souza DO, Oses JP, Donis KC, Rieder CR. Overnight S100B in Parkinson's Disease: A glimpse into sleep-related neuroinflammation. Neuroscience letters. 2015;608:57-63.
Richy FF, Pietri G, Moran KA, Senior E, Makaroff LE. Compliance with pharmacotherapy and direct healthcare costs in patients with Parkinson's disease: a retrospective claims database analysis. Applied health economics and health policy. 2013;11(4):395-406.
Hess LM, Raebel MA, Conner DA, Malone DC. Measurement of adherence in pharmacy administrative databases: a proposal for standard definitions and preferred measures. The Annals of pharmacotherapy. 2006;40(7-8):1280-88.
Mueller C, McDonald K, de Boer RA, Maisel A, Cleland JGF, Kozhuharov N, Coats AJS, Metra M, Mebazaa A, Ruschitzka F, Lainscak M, Filippatos G, Seferovic PM, Meijers WC, Bayes-Genis A, Mueller T, Richards M, Januzzi JL Jr. Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations. European journal of heart failure. 2019;21(6):715-31.
Al-Hassany L, Kloosterboer SM, Dierckx B, Koch BC. Assessing methods of measuring medication adherence in chronically ill children-a narrative review. Patient preference and adherence. 2019;13:1175-89.
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Iraqi Journal of Pharmaceutical Sciences( P-ISSN 1683 - 3597 E-ISSN 2521 - 3512)
This work is licensed under a Creative Commons Attribution 4.0 International License.
